HMPL-306

HMPL-306 is a small-molecule drug developed by Hutchmed. Its target is IDH1 / IDH2 (the sponsor names IDH1/IDH2 (mutant)). ClinicalTrials.gov describes the intervention as: Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukaemia), in acute myeloid leukaemia. The largest, NCT06387069, plans to enrol 316 participants with primary completion expected 2028-12-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.